LungLife AI

Name

LungLife AI

Legal name

LungLife AI, Inc.

Website

https://lunglifeai.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Liquid Biopsy

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Lung Cancer Screening & Pulmonary Nodule Clinic (HLAKANAI)

Keywords

• Liquid biopsy diagnostics
• Lung cancer detection
• Indeterminate lung nodules
• Circulating tumor cells
• Clinical laboratory testing

Headquarters

HQ city

Thousand Oaks

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Testing Services: LungLB test performed in CLIA-certified laboratory as a Laboratory Developed Test (LDT). Revenue generated from test fees per patient sample. Medicare price established at $2,030 per test.
2. Licensing and Royalty Revenue: Following exclusive license and distribution agreement with Circulogene, LungLife receives royalty payments of 20% of net revenue (first year) and 15% thereafter, plus guaranteed minimum royalty payments of $450,000 for first three quarters. Advanced payment of $375,000 received at signing.
3. SEC Filing - Exempt Securities Offering: Form D notice filed for exempt securities offering worth $315,780.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

LungLife AI develops and performs the LungLB® test, a blood-based liquid biopsy that uses rare-cell enrichment combined with FISH-based detection of circulating genetically abnormal cells and AI-enhanced 3D image analysis to classify patients with indeterminate lung nodules as low or high risk for lung cancer. The test is run as a Laboratory Developed Test (LDT) in the company's CLIA-certified, CAP-accredited, NYSDOH-CLEP-permitted laboratory in Thousand Oaks, California, and is targeted at pulmonologists, thoracic physicians, and hospital-based nodule clinics.

Product overview

LungLife AI offers a single unified product: the LungLB test, a liquid biopsy diagnostic solution for early lung cancer detection. The test uses a minimally invasive blood draw combined with AI-enhanced rare-cell enrichment technology and FISH (fluorescent in-situ hybridization) protocol to identify circulating genetically abnormal cells. It is performed in the company's CLIA-certified laboratory in Thousand Oaks, California, and is designed to provide clinicians with additional information to evaluate indeterminate lung nodules following CT scans.

Differentiator

Problem solved

Functional benefit

Brands

• LungLB: A blood-based diagnostic test for early detection of lung cancer using liquid biopsy technology with AI-enhanced analysis. The test is designed to provide clinicians additional information for evaluating indeterminate lung nodules.
• LiquidBiopsy

Products and services

• LungLB Test A blood-based liquid biopsy diagnostic test that uses rare-cell enrichment combined with FISH (fluorescent in-situ hybridization) probes and AI-enhanced 3D image acquisition to identify circulating genetically abnormal cells from a peripheral blood sample. Classifies patients with indeterminate pulmonary nodules as low or high risk for lung cancer. Performed as a Laboratory Developed Test (LDT) in LungLife's CLIA-certified, CAP-accredited laboratory in Thousand Oaks, California. Targeted at pulmonologists, thoracic oncologists, and hospital-based nodule clinics managing the ~1.5 million indeterminate lung nodules identified annually in the US.

Quantifiable outcome

• 81% positive predictive value (PPV) in small nodules (<15mm), compared to ~60% PPV for standard care and 67% PPV for PET scan
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

One partnership is on record.

• Circulogene Theranostics, Inc.coreChannel Partner/ Reseller/ Distributor · 17 April 2025Exclusive license and distribution agreement for commercial distribution of LungLB test in the US. Circulogene receives exclusive rights to improve, develop, market, distribute, and sell the test. LungLife receives advanced payment of $375,000, further $375,000 at completion, plus 20% royalties (reducing to 15% after year 1) with guaranteed minimum $450,000. Circulogene has option to purchase IP for $6.2M less payments received.

Scale indicators11 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Biodesix: Biodesix offers the Nodify Lung blood-based diagnostic tests (Nodify XL2 and Nodify CDT) for evaluating indeterminate pulmonary nodules, directly competing with LungLB in the same clinician use case and patient segment.
• Veracyte: Veracyte's Percepta Genomic Sequencing Classifier uses a bronchoscopy sample to assess lung cancer risk in suspicious nodules; both companies address the indeterminate pulmonary nodule diagnostic decision point for pulmonologists.
• Oncocyte (now Insight Molecular Diagnostics): Oncocyte's DetermaRx is a molecular test for early-stage lung cancer risk stratification, targeting the same pulmonologist/thoracic oncologist customer base with a tissue- or blood-based genomic assay.
• Oncimmune (now Biodesix, brand EarlyCDT-Lung): EarlyCDT-Lung is a blood-based autoantibody test for early lung cancer detection; competes head-to-head with LungLB as a non-invasive blood draw for at-risk patients.

Broad incumbents

• Guardant Health: Guardant360 and Guardant Shield are established liquid biopsy tests for oncology; while broader in scope, Guardant is a major player that could extend into lung nodule management, posing an indirect threat to LungLB.
• Exact Sciences: Exact Sciences is the commercial leader in non-invasive cancer screening (Cologuard); its scale, salesforce and pipeline ambitions represent the kind of large incumbent LungLB would compete against for guideline inclusion and payor coverage.
• Natera: Natera offers Signatera (tumor-informed MRD) and other blood-based oncology tests; an established liquid biopsy operator with broad commercial reach and significant R&D capabilities relevant to the lung cancer space.
• NeoGenomics: NeoGenomics operates a major oncology-focused clinical lab network and offers a menu of molecular and liquid biopsy services, including for lung cancer, comparable in lab-based diagnostic model to LungLife.
• Resolution Bioscience (acquired by Agilent): Resolution Bioscience (now part of Agilent) developed a cfDNA-based liquid biopsy for NSCLC; comparable technology category (blood-based cancer mutation detection) and similar clinical-use positioning as LungLB.

Emerging players

• Circulogene Theranostics: Circulogene is LungLife AI's exclusive US distribution partner and operates its own CLIA lab; strategically aligned commercially and operates a comparable liquid-biopsy lab services model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/LungLifeAI
• Facebookfacebook.com/LungLifeAI
• LinkedInlinkedin.com/company/lunglife-ai

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds13 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LungLife AI